Aging is a major risk factor for both genetic and sporadic neurodegenerative disorders. However, it is unclear how aging interacts with genetic predispositions to promote neurodegeneration. Here, we investigate how partial loss of function of TBK1, a major genetic cause for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) comorbidity, leads to age-dependent neurodegeneration. We show that TBK1 is an endogenous inhibitor of RIPK1 and the embryonic lethality of Tbk1 À/À mice is dependent on RIPK1 kinase activity. In aging human brains, another endogenous RIPK1 inhibitor, TAK1, exhibits a marked decrease in expression. We show that in Tbk1 +/À mice, the reduced myeloid TAK1 expression promotes all the key hallmarks of ALS/FTD, including neuroinflammation, TDP-43 aggregation, axonal degeneration, neuronal loss, and behavior deficits, which are blocked upon inhibition of RIPK1. Thus, aging facilitates RIPK1 activation by reducing TAK1 expression, which cooperates with genetic risk factors to promote the onset of ALS/FTD.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are related neurodegenerative diseases with shared genetic susceptibilities (Ghasemi and Brown, 2017) . ALS primarily leads to the progressive degeneration of motor neurons, while FTD, the second most common cause of early onset dementia after Alzheimer's disease (AD), is characterized clinically by behavioral abnormalities or language dysfunction with progressive degeneration of the frontal and temporal lobes in the brain (Onyike and Diehl-Schmid, 2013) . Activated microglia are a universal feature of ALS/FTD pathology (Lall and Baloh, 2017) .
TBK1 mutations are a major genetic cause of patients with ALS/FTD comorbidity (10.8%) and to a lesser extent causal in ALS alone (0.5%) (Cirulli et al., 2015; Freischmidt et al., 2017) . TBK1, originally identified as a kinase that mediates the ability of TANK to activate nuclear factor kB (NF-kB), is not required for the activation of NF-kB mediated by tumor necrosis factor alpha (TNF-a), interleukin (IL)1 or CD40/CD40L (Pomerantz and Baltimore, 1999) . TBK1 contains an N-terminal kinase domain, a ubiquitin-like domain (ULD), and two C-terminal coiled-coil domains (CCD1 and CCD2). Reduced expression of TBK1 by the mutant alleles associated with ALS/FTD has led to the proposal that haploinsufficiency of Tbk1 is a pathological mechanism. However, it is unclear how reduced expression of TBK1 in individuals with Tbk1 mutations might promote the onset of ALS and FTD.
Aging is a major risk factor in the development of all chronic neurodegenerative diseases, including ALS and FTD (Niccoli et al., 2017) . The mean onset of ALS and FTD is between 50 and 65 years of age. Individuals with familial mutations that predispose them to ALS/FTD may live asymptomatically until middle age. Aging is known to be associated with an increase in neuroinflammation, which is mediated by microglia (Conde and Streit, 2006; Perry et al., 1993) . The kinase activity of RIPK1 plays a central role in mediating neuroinflammation by promoting the activation of microglia in multiple neurodegenerative diseases including ALS, AD, and multiple sclerosis (MS) (Caccamo et al., 2017; Ito et al., 2016; Ofengeim et al., 2015 Ofengeim et al., , 2017 . RIPK1 is suppressed by inhibitory phosphorylations mediated directly by TAK1 and by the kinases activated by TAK1, including MK2 and IkB kinase (IKKs) (Dondelinger et al., 2015; Geng et al., 2017; Jaco et al., 2017; Menon et al., 2017) . Cells with the loss of TAK1-mediated suppression of RIPK1 kinase can directly promote RIPK1-dependent apoptosis (RDA) upon stimulation by TNF-a (Geng et al., 2017; Mihaly et al., 2014; Morioka et al., 2014) . Activation of RIPK1 can also mediate an alternative form of regulated necrotic cell death called necroptosis. This regulated necrosis is mediated by the activation of RIPK1 and subsequent activation of RIPK3 that in turn phosphorylates MLKL (Weinlich et al., 2017) . Although necroptosis has been implicated in mediating the pathology of neurodegenerative diseases including ALS, AD, and MS (Ito et al., 2016; Ofengeim et al., 2015 Ofengeim et al., , 2017 , a corresponding role for RDA in mediating these diseases has yet to be demonstrated. Furthermore, the molecular mechanisms of age-dependent activation of RIPK1 contributing to neurodegeneration in the human CNS remain unclear.
In this study, we investigate the mechanism by which Tbk1 knockout mediates embryonic lethality during development and how TBK1 reduction-of-function can promote neuroinflammation in the adult CNS. We show that the embryonic lethality of Tbk1 À/À mice is completely rescued by the genetic inhibition of RIPK1 kinase activity with Ripk1 D138N knockin mutation, but only partially by Ripk3 knockout. We demonstrate that TBK1 inhibits the activation of RIPK1 by direct phosphorylation of T189/T190 of human/murine RIPK1. TBK1 deficiency sensitizes cells to RDA induced by TNF-a. Furthermore, double heterozygosity of TBK1 and TAK1 is sufficient to promote the activation of RIPK1 by TNF-a. Interestingly, we find that TAK1 levels are decreased in the aging normal human brains (>60 years old). We modeled the interaction of TBK1 and TAK1 in a new animal model of ALS/FTD with TBK1 heterozygosity and myeloid-specific reduction of TAK1 expression. We show that 50% reduction of myeloid TAK1 expression in Tbk1 +/À mice is sufficient to promote all key hallmarks of ALS/FTD including neuroinflammation, TDP-43 aggregation, axonal degeneration, neuronal loss, and behavior deficits, which are rescued by inhibition of RIPK1. Thus, the genetic susceptibility induced by TBK1 heterozygosity can be compounded by aging-induced reduction of TAK1 expression in the brains to promote the activation of RIPK1 and ALS/FTD.
RESULTS

Inhibition of RIPK1 Kinase Activity Blocks Embryonic Lethality of Tbk1 À/À Mice
While Tbk1 +/À mice appear normal, Tbk1 À/À mice die between embryonic day 13.5 (E13.5) and 14.5 (E14.5) with no live births (Bonnard et al., 2000) ( Figure S1A ). We found that the embryonic lethality of Tbk1 À/À mice could be fully rescued by either a heterozygous or a homozygous RIPK1 kinase-dead D138N knockin mutation (Figures 1A and S1B ;Ripk1 D138N/D138N mice remained healthy and fertile as adults (Figures S1C-S1F). Thus, the embryonic lethality of
Tbk1
À/À mice is mediated by abnormal activation of the kinase activity of RIPK1. We performed histological analysis and TUNEL assays on sections from E13.5 wild-type (WT) and Tbk1 knockout embryos.
À/À embryos showed severe liver degeneration with a large number of TUNEL + cells ( Figure 1B ). Tbk1 À/À fetal livers exhibited activated caspase-3 (CC3) and the cleavage of PARP1 as assessed by immunoblot analysis and by immunostaining of CC3 throughout the liver but not the brain ( Figures 1C, 1D , and S1G). Interestingly, these hallmarks of apoptosis were completely blocked by heterozygous or homozygous Ripk1 D138N mutation ( Figures 1B-1D ). In addition, we also observed significant increases in the levels of proinflammatory cytokines and chemokines in Tbk1 Figure 1E ).
RIPK1 activation can be assessed by examining its differential solubility within cells and tissues (Ito et al., 2016; Ofengeim et al., 2015 Ofengeim et al., , 2017 . We found that RIPK1 levels in fetal livers isolated from Tbk1 À/À mice were decreased in the mild detergent (NP-40) fraction but elevated in the insoluble 6 M urea fraction, similar to prior studies that showed RIPK1 activation in human tissue samples from ALS, MS, and AD patients (Caccamo et al., 2017; Ito et al., 2016; Ofengeim et al., 2015 Ofengeim et al., , 2017 . This change in the solubility of RIPK1 in the Tbk1 À/À tissue was rescued upon inhibition of RIPK1 by either heterozygous or homozygous Ripk1 D138N mutation ( Figure 1C Figure 1D ). The activation of RIPK1 in Tbk1 À/À fetal livers was further confirmed by p-RIPK1(S166) immunostaining (Figures S1I and S1J), a marker of RIPK1 activation (Berger et al., 2014; Degterev et al., 2008; Ofengeim et al., 2015) . Genetic knockout of Ripk3 (KO) had only partial efficacy in rescuing embryonic lethality of Tbk1 À/À mice . Using a validated p-RIPK3 (T231/S232) antibody ( Figure S2D ), a marker for its activation (Cho et al., 2009; Sun et al., 2012) , we detected cells with activated RIPK3 in Tbk1
fetal livers that were absent in Tbk1 À/À ;Ripk1 D138N/D138N fetal livers ( Figure 1G ). RIPK3 KO partially prevented the activation of caspase-3 in the fetal livers and restored the viability of only a subset of E13.5 Tbk1 À/À embryos ( Figures S2C and S2E ).
Thus, RIPK3 deficiency can partially suppress the embryonic lethality of Tbk1 À/À mice.
Collectively, these findings suggest that TBK1 suppresses RIPK1 activation during embryonic fetal liver development. TBK1 deficiency promotes RDA by promoting caspase (B) Histological analysis and TUNEL assays were performed on E13.5 liver sections (n = 3).
(C and D) The liver samples (E13.5) were analyzed by immunoblotting (C) and immunostained for cleaved caspase-3 (CC3), RIPK1, or DAPI for nuclei (n = 3) (D).
(E) Quantitative RT-PCR analysis of the mRNA expression of cytokines and chemokines in E13.5 pups' liver (n = 9, mean ± SEM).
(F) The numbers and genotypes of weaned offspring from Tbk1
(G) p-RIPK3 immunohistostaining (brown, n = 3). Microscopic quantification of p-RIPK3 positive cells on liver sections (E13.5) (right). Mean ± SEM. **p < 0.01, ***p < 0.001. See also Figures S1 and S2.
activation during embryonic development. Because inhibition of RIPK1 kinase is more effective in blocking the activation of caspases than RIPK3 deficiency, Ripk1 D138N mutation is more successful than Ripk3 knockout in rescuing the survival of Tbk1 À/À mice.
TBK1 Deficiency Promotes RIPK1 Activation and RDA To understand the mechanism by which TBK1 deficiency promotes RDA, we generated immortalized mouse embryonic fibroblasts (MEFs) derived from WT and Tbk1 À/À littermates.
TBK1 deficiency greatly sensitized cells to TNF-a-induced apoptosis with activation of caspase-8, which did not occur in WT cells; however, TBK1 deficiency had no effect on staurosporine (STS)-induced apoptosis (Figures 2A, 2B , and S3A). The increased sensitivity of Tbk1 À/À MEFs to TNF-a was suppressed by the expression of WT TBK1, but not by TBK1 kinase-dead K38A mutant ( Figure S3B ). NF-kB activation in Tbk1 À/À MEFs stimulated by TNF-a was not altered ( Figure S3C ). There was a slight enhancement of IKKa/b and IkBa phosphorylation in TNF-a-stimulated Tbk1 À/À MEFs compared to WT cells (Figure S3D) . We found that the RIPK1 kinase inhibitor R-7-Cl À O-necrostatin-1 (Nec-1 s) (Degterev et al., 2005) Figures 2D and S3G ). The treatment of TNF-a/cycloheximide (CHX) is an established protocol to induce RIPK1-independent apoptosis (RIA) (Degterev et al., 2005; Zimmermann and Green, 2001) . As expected, Nec-1 s cannot protect against apoptosis of WT MEFs induced by TNF-a/CHX; in contrast, Tbk1 À/À MEFs showed greater levels of apoptosis in response to TNF-a/CHX, which was blunted by Nec-1 s ( Figures 2E, 2F , and S3H). Furthermore, co-treatment with TNF-a/CHX and Nec-1 s reduced the levels of caspase-8 activity in Tbk1 À/À MEFs, but not in Tbk1 +/+ MEFs ( Figure 2F ).
TNF-a/CHX-treated Tbk1 À/À MEFs, but not Tbk1 +/+ MEFs, induced p-RIPK1(S166) and increased CC3 ( Figure 2G ). Furthermore, the increased CC3 in TNF-a/CHX-treated Tbk1 À/À MEFs, but not that of Tbk1 +/+ MEFs, was inhibited by the addition of Nec-1 s ( Figure 2G ).
We further verified this conclusion by using Ripk1
D138N/D138N
MEFs and Tbk1 À/À ;Ripk1 D138N/D138N MEFs. Ripk1
MEFs showed the same sensitivity to TNF-a/CHX-induced apoptosis as WT MEFs (Polykratis et al., 2014) . Interestingly, Tbk1 À/À ;Ripk1 D138N/D138N MEFs showed resistance to TNF-a/ CHX-induced apoptosis ( Figure 2H ). Consistently, Tbk1
MEFs, but not WT MEFs, treated with TNF-a/CHX exhibited RIPK1 activation as indicated by p-RIPK(S166) and CC3, both of which were inhibited in Tbk1 Figure S3I ). Thus, TBK1 deficiency not only sensitizes cells to apoptosis induced by TNF-a alone, but also converts RIA induced by TNF-a/CHX into RDA. Activation of TAK1 kinase activity was previously shown to be a key negative regulator of RDA (Dondelinger et al., 2013; Geng et al., 2017; Mihaly et al., 2014) . To address whether there was any crosstalk between TBK1 and TAK1, we induced RDA in WT and Tbk1 À/À MEFs using TNF-a and a TAK1 inhibitor: (5Z)-7-oxozeaenol (5z7). We found that Tbk1 À/À MEFs were much more sensitive to RDA with increased p-RIPK1 (S166) and caspase-3/caspase-8 activation than that of WT. Pharmacological and genetic inhibition of RIPK1 protected WT and Tbk1 À/À MEFs from RDA and blocked caspase activation ( Figures 2I-2L and S3J-S3M). Thus, TBK1-deficient cells are hypersensitive to RDA mediated by TNF-a and TAK1 inhibition. RIPK3 has been shown to contribute to RDA, in addition to its well-established role in necroptosis (Dondelinger et al., 2013 Figures S3P and S3Q ). These results suggest that RDA is a form of inflammatory apoptosis dependent on RIPK1 kinase activity.
Recruitment of TBK1 into the TNF-RSC Depends on RIPK1 and Linear Ubiquitination TBK1 was shown to be recruited to the TNFR1 signaling complex (TNF-RSC) in a mass spectrometry study (Kuai et al., 2004) ; but the mechanism of TBK1 recruitment to TNFR1 is unclear. We found that the recruitment of TBK1 into the TNF-RSC was largely blocked in Ripk1 À/À MEFs stimulated by TNF-a ( Figure 3A) ; however, recruitment was unaffected by either treatment with Nec-1 s or Ripk1 D138N mutation ( Figures S4A and S4B ). The recruitment of TBK1 to the TNF-RSC was reduced following depletion of cIAP1/2 by SM164 treatment ( Figure 3B ). Furthermore, Hoip À/À MEFs, in which the linear ubiquitin assembly complex (LUBAC) is dysfunctional, showed impaired recruitment of TBK1 to the TNF-RSC ( Figure 3C ). These results suggest that the recruitment of TBK1 into the TNF-RSC depends on RIPK1 and its linear ubiquitination.
To characterize the effect of TBK1 deficiency on the activation of RIPK1 following TNF-a stimulation, we examined whether TBK1 suppresses the activation of RIPK1 in the TNF-RSC. We found that TBK1 deficiency dramatically enhanced the activation of RIPK1 but had no effect on the recruitment of RIPK1 into the TNF-RSC or its ubiquitination ( Figures 3D and S4C) . The treatment of Nec-1 s fully blocked the activation of RIPK1 without affecting the recruitment of RIPK1 into the TNF-RSC ( Figure 3E ). Furthermore, we found that the elevated levels of p-RIPK1(S166) in the TNF-RSC in Tbk1 À/À MEFs was attenuated in the hetero- A-D) MEFs were treated with 10 ng/mL mTNF-a, +/À Nec-1 s (10 mM). Cell death (A and C) and caspase-8 activity (B) were measured by SytoxGreen positivity and Caspase-Glo 8 assay, respectively. The levels of p-RIPK1(S166) and CC3 were determined by immunoblotting (D). Data are represented as mean ± SD. (E-H) MEFs of indicated genotypes were treated with 1 mM CHX for 0.5 hr followed by mTNF-a, +/À Nec-1 s. Cell death was measured by SytoxGreen positivity (E) or CellTiter-Glo assay (H) . Caspase-8 activity was measured by Caspase-Glo 8 assay (F). The levels of p-RIPK1(S166) and CC3 were determined by immunoblotting (G). Data are represented as mean ± SD. (I-L) MEFs were treated with 100 nM (5Z)-7-oxozeaeno for 0.5 hr followed by mTNF-a, +/À Nec-1 s. Cell death was measured by SytoxGreen positivity (I) or CellTiter-Glo assay (K). Caspase-8 activity was measured by Caspase-Glo 8 assay (J) . The levels of p-RIPK1(S166) and CC3 were determined by immunoblotting (L). Data are represented as mean ± SD. ***p < 0.001, n.s., not significant. See also Figure S3 . interaction of FADD and RIPK1 induced by TNF-a in Tbk1
MEFs was blocked by Nec-1 s ( Figure 3G ). Thus, the TBK1 deficiency-induced exaggerated cell death phenotype is dependent upon RIPK1 kinase activity.
TBK1 Inhibits RIPK1 by Direct Phosphorylation
We noted an upward shift of the RIPK1 band by SDS-PAGE analysis of the lysates from HEK293T cells transfected with expression vectors of Flag-RIPK1 and Myc-TBK1. This migrational shift disappeared when co-expressing RIPK1 with kinase mutant TBK1 (K38A) ( Figure S4E ) and following in vitro dephosphorylation using lPPase ( Figure S4F ). These results suggest that TBK1 can phosphorylate RIPK1. The expression of TBK1 inhibited the activation of RIPK1, as assessed by immunoblotting analysis of p-RIPK1(S166) ( Figure S4G ). To determine the effect of TBK1 on RIPK1 kinase activity, we conducted an in vitro kinase assay to compare the ability of RIPK1 auto-phosphorylation in the presence or absence of TBK1. We found that co-incubation with TBK1 significantly reduced the activation of RIPK1 as shown by p-RIPK1(S166) ( Figure S4H ). Thus, TBK1 can directly inhibit the activation of RIPK1 by phosphorylation.
Mass spectrometry analysis was used to determine the site(s) in RIPK1 phosphorylated by TBK1. We found that T189 in human RIPK1 was a dominant phosphorylation site mediated by TBK1 ( Figures S5A and S5B ). T189 human RIPK1/T190 murine RIPK1 is an evolutionarily conserved residue in the activation loop with the motif (DFG.p(S/T/Y).APE) (aa156-196) (Xie et al., 2013) (Figures 4A and S5C ) that is often found in similar kinases and may be subject to phosphorylation to induce a conformational change that can alter kinase activity (Hawley et al., 2014; McCartney et al., 2016) . Because the RIPK1 kinase domain shares kinase fold structural homology with PKC, we aligned the structure of the RIPK1 kinase domain with that of PKC in complex with a substrate peptide from Par3. We identified that D138 residue in the catalytic loop and T189 residue in the activation loop of RIPK1 occupied similar positions to that of D368 in the catalytic loop and T406 in the activation loop of PKC, respectively ( Figure 4A ). Notably, Ripk1 D138N mutation is highly effective in blocking the activation of RIPK1 (Polykratis et al., 2014) . Because T406 in PKC is directly involved in the substrate 
as indicated for 12 hr and then treated with 100 nM A/C heterodimerizer ligand (AP21967) for different periods of time as indicated. The levels of p-RIPK1 (S166) were analyzed by immunoblotting.
(E) Jurkat cells were pre-treated with or without MRT67307 for 0.5 hr and then stimulated with 10 ng/mL hTNF-a. RIPK1 was then immunoprecipitated with p-RIPK1(T189) ab and determined by immunoblotting.
(F) HEK293T cells were transfected with WT, T190E, T190A, or K45M mutant Flag-hRIPK1 and treated with Nec-1 s for 20 hr. Flag-RIPK1 was then immunoprecipitated using anti-Flag and incubated with or without 100 mM ATP or 50 mM Nec-1 s as indicated at 30 C for 30 min. The samples were analyzed by immunoblotting with p-RIPK1(S166).
CrisprKO MEFs were retrovirally reconstituted with HA tagged WT, T190E, or T190A mutant RIPK1. Reconstituted cells were stimulated with TNF-a. Cell death was measured by ToxiLight (n = 4). Mean ± SD. **p < 0.01, ***p < 0.001. See also Figure S5 .
recognition for the kinase due to its position in the activation loop ( Figure 4A ), we hypothesized that T189 residue of RIPK1 might also be directly involved in substrate binding. We tested this hypothesis using a heterodimerization system ( Figure 4B ). TNFa-mediated activation of RIPK1 involves dimerization that is mediated by its C-terminal death domain (Meng et al., 2018) . We tested the ability of heterodimerized WT, D138N, and T190E/A RIPK1 to promote RIPK1 activation. Interestingly, we found that the heterodimerization of WT and D138N RIPK1 resulted in the S166 phosphorylation of D138N RIPK1, but not WT RIPK1 itself ( Figure 4C ), suggesting that activation of RIPK1 requires trans-phosphorylation. This result also explains why heterozygous Ripk1 D138N/+ cells and mice are also defective in the activation of RIPK1 and protected from TBK1 deficiency.
On the other hand, the heterodimerization of WT RIPK1 with either T190E or T190A mutant resulted in no S166 RIPK1 phosphorylation ( Figure 4D ), supporting the hypothesis that T190 is a critical residue involved in the substrate recognition for RIPK1 as WT RIPK1 cannot phosphorylate T190E or T190A RIPK1.
We developed an anti-p-RIPK1(T189) antibody ( Figure S5D ). Phosphorylation of T189 human RIPK1 was detected upon incubation with TBK1 both in vitro and in HEK293T cells. This phosphorylation was inhibited by TBK1/IKKε inhibitor MRT67307 ( Figures S5E-S5G ). Furthermore, T189 phosphorylation of endogenous RIPK1 was detected in Jurkat cells stimulated by TNF-a, which was similarly inhibited by MRT67307 ( Figure 4E ).
Our data clearly indicate that TBK1 can directly phosphorylate RIPK1 at T189. We next characterized the functional role of this phosphorylation on the kinase activity of RIPK1 in vitro. We found that both T189E and T189A RIPK1 mutants were catalytically inactive ( Figure 4F ). We further characterized the role of T190/ T189 on cell death. While re-introduction of WT RIPK1 could rescue the sensitivity of Tbk1
CrisprKO MEFs to TNFa-induced RDA, neither T190A nor T190E RIPK1 could restore this sensitivity (Figures 4G and S5H) . Taken together, these results suggest that phosphorylation of T190/T189 RIPK1 by TBK1 inhibits RIPK1 by blocking trans-activation of RIPK1.
Over-Activation of TAK1 in TBK1-Deficient Cells Similar to TBK1, TAK1 can also directly mediate inhibitory phosphorylation on RIPK1. S321 is one of the multiple sites on RIPK1 that can be phosphorylated by TAK1 (Geng et al., 2017) . We found that the levels of p-RIPK1(S321) in Tbk1 À/À MEFs upon TNF-a stimulation were increased compared to that of WT MEFs (Figure 5A ). Furthermore, p-IKKa/b(S178/S180), another known substrate of TAK1 (Chen, 2012; Mihaly et al., 2014) , was also increased in Tbk1 À/À MEFs stimulated by TNF-a (Figures 5A and S3D). Because both TAK1 and TBK1 are endogenous inhibitors of RIPK1, these data suggest that TAK1 may be over-activated in TNF-a-stimulated TBK1-deficient cells to compensate for the loss of TBK1. The over-activation of TAK1 in TBK1-deficient cells was further confirmed by an in vitro kinase assay (Figure 5B) . Consistently, the TAK1 sites on RIPK1 and IKKa/b as well as the downstream targets of TAK1, such as p-JNK, p-p38, and p-ERK (Mihaly et al., 2014) , were all hyperphosphorylated in the Tbk1 À/À MEFs in response to TNF-a ( Figures S6A and S6B ).
We questioned how aging might play a role in the onset of ALS and FTD in individuals carrying a TBK1 heterozygous mutation.
Because hyperactivation of TAK1 in a TBK1-deficient background might compensate for the loss of TBK1, we wondered if aging might have an effect on the expression of TAK1 in human brains. We analyzed a microarray expression dataset that examined transcriptional changes during normal aging of the human brain. The mRNA levels of Tak1 were decreased 1.33-fold in brains from aged individuals (>60 years old) compared to young adults (<40 years old) ( Figure S6C) ; while the expression of TBK1 did not change during aging (Loerch et al., 2008) . A striking reduction in the protein levels of TAK1 in aged brains was demonstrated by immunoblot analysis of human prefrontal cortex samples from individuals of different ages who passed away due to non-neurological causes ( Figure 5C ). The mean age of onset for ALS/FTD is $60 years old (White and Sreedharan, 2016) ; in particular, the current genetic data suggest a high disease penetrance of TBK1 loss-of-function variants in mutation carriers older than 60 years (Freischmidt et al., 2017) . Interestingly, we found a further reduction of TAK1 expression in ALS brains compared to age-matched controls ( Figure S6D ). These data suggest that an age-dependent reduction of TAK1 expression might be a key contributing factor in the onset of ALS/FTD.
To test if double heterozygosity of TBK1 and TAK1 might be sufficient to drive RIPK1 activation, we generated Tbk1 S6F ). Taken together, our results demonstrate that double heterozygosity of TBK1 and TAK1 promotes RIPK1 activation and RDA and suggest that TAK1 reduction during that normal aging in the CNS may contribute to the susceptibility of the brain to neurodegeneration.
Double Heterozygosity of TBK1 and TAK1 Promotes Microglia Activation
We found that in both mouse and the human brains from younger individuals, TAK1 was highly expressed by microglia ( Figures  S6G and S6H) . Furthermore, the levels of TAK1 were reduced in microglia in brains from older individuals ( Figure S6H ). Because TBK1 is also highly expressed in microglia , we hypothesized that heterozygosity of myeloid TAK1 expression in Tbk1 +/À mice could be sufficient to promote the activation of RIPK1 to mediate neurodegeneration. Figure 6A ).
We also analyzed the global profile of microglia isolated from brains and spinal cords of adult mice by FCAS using cell surface levels of major histocompatibility complex class II (MHC II), a classical M1 biomarker for pro-inflammatory microglia (Barron, 1995) . We found that the cell surface levels of MHC-II in microglia isolated from both spinal cords and brains of adult The samples were analyzed by immunoblotting with p-TAK1(T184/T187).
(C) Immunoblotting analysis of human frontal cortex (12 young and 12 older individuals) (top) and the quantification of TAK1 levels (bottom) (mean ± SEM).
(D) MEFs of indicated genotypes were stimulated by Flag-mTNF-a. TNF-RSC was immunoprecipitated using anti-FLAG resin. The activation of RIPK1 was analyzed by immunoblotting using anti-p-RIPK1(S166) ab.
(E-G) MEFs were treated with mTNF-a, +/À Nec-1 s. Cell death was measured by CellTiter-Glo assay (E and F) (mean ± SD). The levels of CC3 were determined by immunoblotting (G). *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S6 .
Tbk1
+/À ;Tak1 DM/+ mice were significantly increased compared to that of WT, which were suppressed upon inhibition of RIPK1 by Ripk1 D138N mutation in Tbk1 +/À ;Tak1 DM/+ ;Ripk1 D138N/+ mice ( Figure 6B ).
We analyzed the expression profile of microglia isolated from the brains of newborn mice by RNA sequencing (RNA-seq). ;Tak1 DM/+ microglia in RIPK1-dependent fashion (E).
(F) The cytokine profiles in the spinal cords from 6-month-old mice were measured by qPCR (n = 3, mean ± SEM). *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S6 . Figure 6F ). While no cell death was detected in Tbk1
DM/+ primary microglia ( Figure S6L ), there were increases in inflammatory responses at both steady states and upon TNF-a treatment in Tbk1
;Tak1 DM/+ primary microglia, both of which were inhibited by Ripk1 D138N/+ mutation ( Figure S6M ). Furthermore, RIPK1, but not JNK or ERK, was also significantly activated in Tbk1
;Tak1 DM/+ primary microglia treated with TNF-a ( Figures   S6N and S6O ). Taken together, these results suggest that double heterozygosity of TAK1 and TBK1 in myeloid lineage is sufficient to promote neuroinflammation by microglia.
TBK1/TAK1 Double Heterozygosity Promotes Axonal Defects in Spinal Cords
Because these data suggest that TBK1 haploinsufficiency in the context of an aging-dependent reduction of TAK1 leads to a RIPK1-dependent neuroinflammatory response, we next examined whether this response could lead to a non-cell autonomous deleterious phenotype in the CNS. We therefore characterized the impact of TBK1/TAK1 double heterozygosity in the spinal cords of Tbk1 +/À ;Tak1 DM/+ mice. We observed a significant reduction in the number of motor axons and abnormal myelination in the white matter of the ventrolateral spinal cords of Tbk1 +/À ;Tak1 DM/+ mice (6 months old), similar to the axonal pathology observed in the Optn À/À mice spinal cords (Ito et al., 2016) Figure 7G ). On the other hand, the body weight of these mice showed no difference ( Figure S7H ). Thus, 50% reduction of TAK1 expression in myeloid lineage in Tbk1 +/À background promotes cell death, motor axonal pathology, denervation of muscle endplates, and hindlimb weakness, all in a RIPK1-dependent manner. mice, the number of NeuN-positive neurons in the cortex was reduced by 15%, which was rescued by genetic inhibition of the kinase activity of RIPK1 in the Ripk1 D138N line ( Figure 7H ).
The presence of cytosolic TDP-43 inclusion in the CNS is a key neuropathological feature of FTD/ALS (Neumann et al., 2006) . We found cytoplasmic inclusions of TDP-43 in $6% cells in the cortex of 6-month-old Tbk1 +/À ;Tak1 DM/+ mice ( Figure 7I ).
However, no neuronal loss or TDP-43 inclusions were found in 2 months old Tbk1
Increased levels of high-molecular-weight RIPK1 were found in both brain and spinal cord of Tbk1 +/À ;Tak1 DM/+ mice, which was inhibited by Ripk1 D138N/+ mutation ( Figure S7L ). RIPK1 activation was further confirmed by p-RIPK1(S166) + immunostaining in the brain of Tbk1
;Tak1 DM/+ mice, which was inhibited in Tbk1 +/À ;Tak1 DM/+ ;Ripk1 D138N/+ mice ( Figure S7M ).
To determine whether the combination of pathological features described above impacted behavior, we performed the bright open field test that assesses anxiety-like behavior in a novel environment. Tbk1
DM/+ mice exhibited a decreased tendency to explore the center of the open field ( Figures 7J and S7N ), suggestive of anxiety-like behavior. This behavior abnormality in the Tbk1 +/À ;Tak1 DM/+ mice was further confirmed by the elevated plus maze test ( Figures 7K and S7O ). These data suggest that de-repression of RIPK1 kinase activity leads to a neuroinflammatory environment in the CNS and onset of ALS/FTD-like pathology including axonal pathology, TDP43 inclusions, neurodegeneration, and corresponding behavioral phenotypes.
DISCUSSION
In this study, we demonstrate that TBK1 deficiency promotes RDA and inflammation to induce embryonic lethality and ;Ripk1 D138N/+ , n = 10). Mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, n.s., not significant.
See also Figure S7 .
neurodegeneration in aging upon reduction of TAK1 expression. Because embryonic lethality in Tbk1 À/À mice can also be prevented upon deletion of Tnfr1 (Bonnard et al., 2000) or Tnf (Matsui et al., 2006), our results suggest that RIPK1 is a key mediator of deleterious events downstream of TNFR1 by promoting not only necroptosis, but also RDA and inflammation. Hence, our results suggest that inhibition of RIPK1 activation is important for both normal embryonic development and the prevention of age-related neurodegenerative diseases. Furthermore, we propose that the aging-dependent reduction of TAK1 expression and reduced RIPK1 suppression in the human brains might be important not only as a mechanism to interact with the heterozygosity of TBK1 in individuals with inherited TBK1 mutations to promote the onset of ALS/FTD, but also to sensitize a variety of age-dependent chronic neurodegenerative diseases such as AD and Parkinson's disease. Tbk1 À/À MEFs stimulated by TNF-a display dramatic activation of RIPK1 in complex I, which may represent a critical step in the activation of RDA. Most activated RIPK1 in necroptosis stimulated by TNF-a/CHX/zVAD is located in complex II (Dziedzic et al., 2018) . We have previously shown that deficiency in OPTN, a ubiquitin binding protein that binds to RIPK1, leads to stabilization of RIPK1 due to reduced K48 ubiquitination and increased RIPK1 activation in complex II (Ito et al., 2016) . Thus, disruption in the mechanisms that suppress the activation of RIPK1 may occur at different levels downstream of TNFR1 signaling to promote neurodegeneration. TBK1 plays pivotal roles in antiviral innate immunity by mediating the activation of interferon regulatory factor (IRF) 3, leading to the induction of type I interferons (IFN-a/b). Multiple viruses have evolved elaborate strategies to evade anti-viral responses by targeting TBK1. Thus, viral inhibition of TBK1 might provide a sensitized background, as that of TBK1 heterozygosity, in aging brains to promote neuroinflammation and neurodegeneration. Taken together, our findings suggest that age-dependent reduction of RIPK1 inhibition in the brain might predispose to neuroinflammation and neurodegeneration in the setting of genetic or environmental stresses.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS Animals
Tbk1
+/À mice and Tak1 fl/fl mice (Ishii et al., 2008; Sato et al., 2005) , Ripk1 D138N mice (Polykratis et al., 2014) and Ripk3 À/À mice (Newton et al., 2004) were used in this study. Cre/Cre mice were from The Jackson Laboratory (Catalog No. 004781).
Mouse husbandry
Mice were group-housed in a 12 hr light/dark cycle (light between 07:00 and 19:00) in a temperature-controlled room (21.1 ± 1.1 C) at Harvard Medical School with free access to water and food and maintained according to protocols approved by the Harvard Medical School Animal Care Committee on Animal Care. The ages of mice are indicated in the figure legends or methods. Sex was not determined for embryos or neonatal pups. For analyses of older animals (> P21), only male mice were used unless indicated otherwise.
All experiments with mice were performed with the approval of the Harvard Medical School Animal Care Committee.
Mouse genotyping
Genomic DNA was extracted from mouse tails, PCR was performed with Ex Taqâ DNA Polymerase (TaKaRa) or Phusionâ HighFidelity DNA Polymerase (NEB). Amplicons were analyzed by agarose gel electrophoresis. PCR primers, PCR conditions, and expected amplicon sizes are indicated in Table S1 .
Human tissues
The research involving human pathological samples was approved by the Institutional Review Board (IRB) of Harvard University. The postmortem brain tissues were neuropathologically normal and derived from non-demented individuals. Human cortical gray matter samples were dissected from the frontal pole (Brodmann area 9, 10) and snap-frozen in liquid nitrogen and stored at À85 C. Human brain samples with a tissue pH > 6.5 were used to exclude prolonged terminal hypoxia. The brain tissues were allocated to two experimental groups as young % 40 year and aged R 70 year regardless of sex. For western blotting, tissues were homogenized in RIPA buffer containing protease inhibitors (Complete, Roche) with Na 3 VO 4 (1 mM). Tissues were homogenized, sonicated, and centrifuged at 10,000 rpm at 4 C and the protein concentrations were adjusted to 1 mg/ml based on protein assay (Thermo protein assay). Samples were boiled in 1 3 SDS sample buffer containing DTT and resolved by 8% SDS-PAGE.
Cell lines and cell culture All cells were cultured at 37 C with 5% CO 2 . Human cell lines were cultured as follows: HEK293T (ATCC) in DMEM (GIBCO) with 10% FBS (GIBCO); Jurkat (ATCC) in RPMI-1640 (Life Technologies) with 10% FBS. HEK29T is of female origin and Jurkat is of male origin, both cell lines are authenticated. All murine cell lines and primary cells were cultured in DMEM with 10% FBS.
Generation and immortalization of MEFs
MEFs were isolated from E11-13 embryos using trypsin/EDTA and sieved through 70-micron filter. Primary MEFs were cultured in high glucose DMEM supplemented with 15% FBS, non-essential amino acids, sodium pyruvate, penicillin, streptomycin and amphotericin B. At passages 4-6, primary MEFs were immortalized by transfection with SV40 large T antigen-expressing plasmid (Addgene 22298) using Lipofectamine 2000. Sex was not determined for embryos.
Primary microglia culture
Forebrains of 2-d-old mouse pups were digested with 0.01% trypsin and triturated with DMEM containing 10% heat-inactivated fetal bovine serum and 1% penicillin-streptomycin. Dissociated cells were plated onto poly-d-lysine coated 75 cm 2 flasks and changed the medium after 7 days, then the cells were cultured for another 7 days. Following an initial 5 min shake of the culture, microglia were collected and cultured in DMEM+10%FBS. The quality of purification was analyzed by FACS using CD11b as a marker for microglia (> 90% CD11b + ). Sex was not determined for neonatal pups.
METHOD DETAILS
Plasmids construction
Full-length cDNAs for mouse/human RIPK1 and TBK1 were PCR-amplified from the plasmid library and cloned into pcDNA3.1 using Phantaâ Max Super-Fidelity DNA Polymerase (Vazyme Biotech) with appropriate tags. Retroviral virus production used Myc/HA tagged pMSCV-blasticidin vector. pMSCV was used as the plasmid backbone for all of the constructs used for reconstitution study. Mutant hRIPK1(T189A, T189E, K45M), mRIPK1(D138N, T190A, T190E) and mTBK1(K38A) were generated using MutExpress II mutagenesis kit (Vazyme Biotech). cDNA encoding truncated mRIPK1 (aa1-567, WT or mutant), DmrA/C, myc/HA, GFP were ligated through Golden Gate assembly method and cloned into the XhoI/EcoRI sites in the pMSCV-blasticidin/puromycin vector. For protein purification, cDNA encoding hRIPK1(1-294) with 3C PreScission site at N terminus was cloned into NdeI/EcoRI sites in pET-28a plasmid for E.coli expression, and cDNA encoding HA tagged hRIPK1(1-330, WT or mutant) was cloned into EcoRV/NotI sites in pEBG plasmid for mammalian expression. All plasmids were verified by DNA sequencing and the details of the plasmids sequences are available upon request.
FACS of microglia from adult mice
Mice were sacrificed, and the brains and spinal cords were isolated. After removal of cerebellum, the brain was chopped with a razor blade followed by homogenization with a 19-gauge needle and incubation in Accutase (Sigma) for 10 min at 37 C. The brain lysates were homogenized twice with a 21-gauge needle. The suspension was filtered through 40 mm cell strainer and centrifuged at 300 3 g. The pellet was resuspended in PBS, and 25% BSA (IgG & Protease Free from Jackson ImmunoResearch) in PBS was added 1:1 on top. This suspension was centrifuged for 10 min (RT) at 1200 3 g. Myelin debris in the top layer supernatant was removed. The pellet was resuspended in ACK Lysing Buffer (Thermo Fisher) and incubated for 5 min (RT). The cells were centrifuged for 5 min at 4 C at 300 3 g. The resulting pellet was blocked with Rat Anti-Mouse Fc (BD Biosciences) and stained with a Live/Dead marker, CD11b, CD45, CX3CR1, and Ly6C antibodies, for subsequent FACS analysis using a FACSAria III (BD Biosciences) and FACSDiva Software (BD Biosciences). Live microglia were identified as CD11b
High CD45 Intermediate Ly6C Low CX3CR1 High .
RNA-seq RNA was isolated from primary microglia in culture using Quick-RNA MiniPrep Plus kit (Zymo Research) with 3 replicates for each genotype. Each library was prepared using the Smart-seq2 protocol (Picelli et al., 2013 ) with a tagged oligo (dT) primer to make first strand cDNA from 1 ng total RNA input. Double-stranded cDNA was generated for library construction with 12 cycles of PCR and 0.3 ng of cDNA was used as input to the NexteraXT kit (Illumina). Libraries were sequenced with a NextSeq (Illumina) to generate 50 base paired end reads. Reads were aligned to the mm10 UCSC mouse transcriptome and expression values were determined using RSEM (Li and Dewey, 2011) .
Reconstitution of Tbk1 À/À MEFs and Tbk1
À/À
;Ripk1
CrisprKO MEFs For viral packaging, HEK293T cells were transfected with different vectors using PEI (Polysciences, Cat#23966-2). The medium was changed after 6h, and collected at 48h post-transfection. The virus-containing supernatant was then used to infect MEFs. Twelve hours after infection, viral infected MEFs were selected with blasticidin (10 mg/ml). For Tbk1
CrisprKO MEFs, RIPK1 was knocked out in Tbk1 +/+ and Tbk1 À/À MEFs using CRISPR/Cas9 method. The target site for mRIPK1 was designed as 'TGTGAAAGT CACGATCAACG' (for sgRIPK1) and GFP target site 'GAGCTGGACGGCGACGTAAA' (for sgGFP) as a negative control, oligos were synthesized and ligated into LentiCRISPR V2-puro vector (Addgene plasmid # 52961) through standard protocol to generate sgRIPK1 and sgGFP. HEK293T cells were transfected with sgRIPK1 or sgGFP and pMD2.G (Addgene plasmid # 12259), psPAX (Addgene plasmid #12260) in a ratio of 4:1:3. The virus-containing supernatant was harvested as described above and used to infect Tbk1 +/+ or Tbk1 À/À MEFs. Twelve hours after infection, virus infected MEFs were selected using puromycin (2 mg/ml) and validated. In order to reconstitute RIPK1 into this gRNA containing MEFs, a synonymous mutation was designed at the gRNA target site through amplifying N-terminal fragment (F: 5 0 -AACCGTCTCGGATCCATGCAACCAGACATGgaaTTGGACAATA TTAAGATGGC-3 0 , R:5 0 -AAC CGTCTCCTTAATaTGgAAaTCtCGgTCtACcAatATATTCTCA GGCTTCAGGTCCTTGT-3 0 ) and C-terminal fragment (F:5 0 -AACCGTC TCATTAAGATAGC CGATCTTGGTGTGGC-3 0 , R:5 0 -AACCGTCTCGAATTCTTAGCTCTGGCTGGCAC-3 0 ), and ligated into BamHI/ EcoRI sites using Golden Gate assembly method in modified pMSCV-blasticidin vector with a HA-tag at N terminus. Virus-containing supernatant was harvested and used to infect Tbk1 À/À MEFs as described above and positive MEFs were selected using blasticidin (10 mg/ml) and verified.
Generation of RIPK1 heterodimerization system
The DmrA/C heterodimer system is from ARIAD's ARGENT cell signaling regulation kit (Bayle et al., 2006) . The addition of rapamycin derivative AP21967 allows the heterodimerization of FKBP(DmrA)-fused-tagged protein with FRB T2098L (DmrC)-fused-tagged protein, but does not allow homodimerization of FKBP(DmrA)-fused-tagged protein by itself, or that of FRB T2098L (DmrC)-fused-tagged protein by itself. AP21967 was used to induce heterodimerization of murine RIPK1 DDD -DmrA-Myc and murine RIPK1 DDD -DmrC-HA-GFP. The details and molecular weight of the two constructs are shown in Figure 4B . HA and Myc tags were used for antibody identification and GFP tag was fused to DmrC for separation of two RIPK1 fusion proteins on SDS-PAGE.
Analysis of cytotoxicity and viability
The rates of cell death were measured in triplicate or quadruplicate in a 96-well or 384-well plate by using SYTOX Green Nucleic Acid Stain (Invitrogen) or ToxiLight Non-destructive Cytotoxicity BioAssay Kit (Lonza). The intensity of luminescence was determined in an EnSpire Multimode Plate Reader (PerkinElmer). Cytotoxicity is expressed as percentages of cell death per well after deducting the background signal in non-induced cells and compared to that of the maximal cell death with 100% Lysis Reagent. The rates of cell viability were determined by using CellTiter-Gloâ Luminescent Cell Viability Assay (Promega) following the manufacturer's protocol and the results are expressed as percentages of luminescence intensity per well after deducting the background signal in blank well and compared to that of the viability in the non-treated wells.
Caspase-8 activity assay Caspase-Glo 8 assay (Promega) was used to detect the activity of caspase-8 in cells by following manufacture's protocol.
TUNEL TUNEL assay was used to detect dead cells with DNA fragmentation using In Situ Cell Death Detection Kit, POD (Roche) by following manufacture's protocol.
Histology and immunochemistry
Animals were sacrificed and perfused with PBS followed by 4% paraformaldehyde. Then, 20-mm sections were prepared on a cryostat. For immunostaining, tissue sections were mounted and blocked with 10% normal goat serum and 1% BSA, and then incubated with primary antibodies at 4 C overnight. Images were collected with a Nikon Ti-E confocal microscope equipped with A1R scan head with spectral detector and resonant scanners and acquired with Nikon elements software. Z series optical sections were collected with a step size of 0.2 microns, using a Prior Proscan focus motor.
Protein expression and purification
Recombinant His-RIPK1(aa1-294) protein fragment was expressed in BL21(DE3) E. coli after induction with 0.1mM IPTG overnight at 16 C. Bacteria were harvested by centrifugation and cell pellet was lysed in 50mM Tris-HCl[pH8.0] containing 5% Triton X-100 with sonication at 4 C for 15min. The lysates were centrifuged and resuspended again in 50mM Tris-HCl[pH8.0]/1M NaCl with sonication at 4 C for 15min. The lysates were then centrifuged and resuspended in 50mM Tris-HCl[pH8.0]/6M Guanidine-HCl with sonication at 4 C for 30min. The final lysates were cleared by centrifugation. His-tagged RIPK1 was purified using Ni-NTA agarose (GE Healthcare) and further purified by HPLC.
In vitro kinase assay Flag-tagged RIPK1 was immunoprecipitated from HEK293T cells expressing Flag-RIPK1 and washed with high-salt lysis buffer [5% glycerol, 0.5% NP-40, 500mM NaCl and 50mM Tris-HCl (pH7.4)] for 5 times and then with water for 3 additional times. 10 mL beads with Flag-RIPK1 were resuspended in 24 mL 1 3 kinase buffer [20 mM MgCl 2 ,100 mM ATP, 2 mM DTT, 50 mM inhibitors as indicated and 40 mM Tris-HCl(pH7.5)] after the final wash step. TBK1 kinase assays were performed with 50ng TBK1 protein and recombinant RIPK1 kinase domain (aa 1-294) (5 mg) purified from E. coli or truncated RIPK1(aa1-330) (400 ng) expressed and purified from 293T cells in 24 mL 1 3 kinase buffer. Kinase reactions were performed for 30min at 30 C and quenched by the addition of 6 mL 5 3 sample loading buffer and boiling at 100 C for 10min.
Mass spectrometry and data analysis Recombinant His-RIPK1 kinase domain (aa 1-294) purified from E. coli (20 mg) was incubated in vitro with or without recombinant full length His-TBK1 purified from sf9 cells (200 ng) in the presence of 100 mM ATP at 30 C for 30min. The samples were resolved by SDS-PAGE and stained with Coomassie blue. The RIPK1 band was cut and digested in gel. The resulting peptides were subjected to the enrichment of phosphorylated peptides by using TiO 2 . The enriched phosphorylated peptides were analyzed on the Q Exactive HF mass spectrometer (Thermo Scientific). The identification and quantification of phosphorylated peptides was done by MaxQuant (Cox and Mann, 2008) . The tandem mass spectra were searched against UniProt human protein database together with a set of commonly observed contaminants. The precursor mass tolerance was set as 20 ppm, and the fragment mass tolerance was set as 0.1 Da. The cysteine carbamidomethylation was set as a static modification, and the methionine oxidation as well as serine, threonine and tyrosine phosphorylations were set as variable modifications. The FDR at peptide spectrum match level and protein level were controlled below 1%.
In vitro dephosphorylation assay with lPPase For lPPase treatment after immunoprecipitation, beads were resuspended with manufacturer-provided buffer (2 mL 10 3 PMP, 2 mL 10mM MnCl 2 ), lambda protein phosphatase(800U) in 20 mL total volume. Dephosphorylation reactions were performed for 30min at 30 C and stopped by addition of 6 mL 5 3 sample loading buffer and boiling at 100 C for 10min.
Transmission electron microscopy Animals were sacrificed and perfused with PBS followed by fixation solution of 2.5% glutaraldehyde/2% paraformaldehyde in 0.1 M sodium cacodylate buffer (pH 7.4). Small pieces (1-2mm3 cubes) of lumbar spinal cords (L1-L4) and the associated ventral roots from a perfusion fixed animal were post-fixed for at least 2 hr at RT in the above fixative, washed in 0.1M cacodylate buffer and post-fixed with 1% osmiumtetroxide (OsO 4 )/1.5% potassium ferrocyanide (KFeCN6) for 1 hr, washed in water 3 3 and incubated in 1% aqueous uranyl acetate for 1hr, followed by 2 washes in water and subsequent dehydration in grades of alcohol (10min each; 50%, 70%, 90%, 2 3 10min 100%). The samples were then put in propyleneoxide for 1 hr and infiltrated overnight in a 1:1 mixture of propyleneoxide and TAAB Epon (Marivac Canada St. Laurent, Canada). The samples were then embedded in TAAB Epon and polymerized at 60 C for 48 hr. Ultrathin sections (60nm) were cut with a Reichert Ultracut-S microtome, picked up on to copper grids stained with lead citrate and examined using a JEOL 1200EX Transmission electron microscope or a TecnaiG 2 Spirit BioTWIN and images were recorded with an AMT 2k CCD camera. Myelination, axonal morphology and g-ratios of different genotypes were determined from counting of $200 axons in the ventrolateral lumbar spinal cord white matter of 3 mice for each genotype at 6 months of age using ImageJ analysis.
Axonal diameter and g-ratio determination
The axonal diameters were measured on EM images using ImageJ. G-ratio was determined as the ratio of inner axonal diameter to the outer diameter of each axon fiber. $200 axons from the ventral lateral white matter of lumbar spinal cords (L1-L4, one section each) of 3 mice (6 months old) were measured in each analysis.
Animal behavior study
The animal behavior study was conducted by the NeuroBehavior Laboratory, Harvard Institute of Medicine. The mouse genotypes were blinded to the testers. For data analysis, Shapiro-Wilks's test was used to check suitability of parametric tests. All the pairwise comparisons are significant using this method.
Locomotor activityMice were tested in locomotor activity chambers under low light to assess spontaneous exploratory activity. The apparatus consisted of 27.3cm 3 
Characterization of neuromuscular junctions
Tibialis anterior muscles from mice at 12 weeks of age were dissected, pinned in mild stretch and immersion-fixed for 30 min in 4% paraformaldehyde at RT. Fixed muscles were cryoprotected in 30% sucrose/phosphate-buffered saline (48h at 4 C). 50-mm thick frozen sections were cut longitudinally through the entire muscle. Sections were incubated overnight at RT in a cocktail of primary antibodies with anti-neurofilament 2H3 (1:250) and anti-SV2 (1:250), in PBS, 0.3% Triton X-100, 3% BSA. Sections were washed and incubated overnight with an Alexa Fluor-488 conjugated anti-mouse IgG1 and Alexa Fluor-594 conjugated a-bungarotoxin (Invitrogen), each at a 1:1000 dilution in the same buffer as above. Sections were then mounted in fluorescence mounting medium and imaged using fluorescence microscopy at 40x magnification and analyzed using ImageJ. The data were obtained from analyzing $100 NMJs from 3 mice of each genotype (6 months old).
QUANTIFICATION AND STATISTICAL ANALYSIS
Multiple comparisons were statistically evaluated using a two-tailed Student's t test. Differences were considered statistically significant if p < 0.05(*); p < 0.01 (**) or p < 0.001(***). Pairwise comparisons between two groups were performed using the Student's t test.
For multiple comparisons with the three genotypes, we performed one-way Anova. Two-way Anova was performed for multiple comparisons with genotypes, and the results obtained by standard least-squares fits followed by appropriate post hoc tests are shown. RNA sequencing reads were mapped against mouse mm10 transcriptome using STAR and size factors of each sample were calculated for the normalization of the count data by DEseq2 in R version 3.3.1. The heatmaps were generated using the heatmap function in the stats library.
DATA AND SOFTWARE AVAILABILITY
The accession number for the sequencing data reported in this paper is GEO: GSE116613. The Mendeley link for the original blots reported in this paper is https://doi.org/10.17632/pcch8m27ty.1. (E) The embryos of indicated genotypes at E13.5 were isolated and dissected. Tissue lysates from the livers were subject to analysis by immunoblotting using indicated antibodies.
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